Black Diamond Therapeutics Inc (nasdaq:BDTX) Share Price

Company Profile

Business description
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
Contact
245 First Street
18th Floor
CambridgeMA02142
USA
T: +1 617 252-0848
https://www.blackdiamondtherapeutics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
21

Recommended

We think the floundering stock price is not reflective of underlying asset value.

Brian Han | 10 April 2026

Near-term cost growth does not change our long-term view.

Shane Ponraj, CFA | 10 April 2026

US stores are struggling, but our investment thesis hinges on the Australian rollout.

Johannes Faul, CFA | 09 April 2026

Index	Last price	Change	% Change
All Ordinaries	9,155.80	34.00	0.37%
CAC 40	8,259.60	13.81	0.17%
DAX 40	23,803.95	3.04	-0.01%
Dow JONES (US)	47,916.51	269.29	-0.56%
FTSE 100	10,600.53	2.95	-0.03%
HKSE	25,893.54	141.14	0.55%
NASDAQ	22,902.89	80.48	0.35%
Nikkei 225	56,924.11	1,028.79	1.84%
NZX 50 Index	13,181.44	92.37	-0.70%
S&P 500	6,816.82	7.84	-0.11%
S&P/ASX 200	8,960.60	36.20	0.41%
SSE Composite Index	3,986.22	20.05	0.51%